Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactions

OBJECTIVE: To review the pharmacokinetics and pharmacodynamics of oral and intravenous azithromycin compared with other macrolide antibiotics, and to evaluate these differences and their relation to clinical effectiveness. DATA SOURCE: A MEDLINE search (1966-May 1998) was performed to identify applicable English-language clinical, animal, and microbiologic studies pertaining to pharmacokinetic and pharmacodynamic parameters. STUDY SELECTION: Relevant studies concerning microbiology, pharmacokinetics, tissue concentrations, pharmacodynamics, and the clinical effects of these parameters were selected. DATA SYNTHESIS: The structural modification that distinguishes the azalide antibiotics from the macrolide antibiotics is responsible for the pharmacokinetic and pharmacodynamic behavior of azithromycin, resulting in the high and sustained tissue and intracellular concentrations seen with this agent. Drug delivery to the site of infection by phagocytes and fibroblasts is the hallmark of azithromycin's tissue-directed pharmacodynamics, allowing for convenient once-daily, 5-day regimens for most infections that respond to oral therapy and 7-10 days for more serious infections requiring initial intravenous therapy. Metabolism is via hepatic pathways other than cytochrome P450, thus minimizing the risk of drug interactions. CONCLUSIONS: Compared with other macrolide antibiotics, the unique pharmacokinetic and pharmacodynamic features of azithromycin offer the potential for improved efficacy and safety from drug interactions. These attributes, combined with its once-daily dosing schedule, make azithromycin suitable for the treatment of many types of bacterial infection.

This article has been cited by other articles:

				M. Lucchi, B. Damle, A. Fang, P. J. de Caprariis, A. Mussi, S. P. Sanchez, G. Pasqualetti, and M. Del Tacca Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin J. Antimicrob. Chemother., April 1, 2008; 61(4): 884 - 891. [Abstract] [Full Text] [PDF]

				M. A. Drehobl, M. C. De Salvo, D. E. Lewis, and J. D. Breen Single-Dose Azithromycin Microspheres vs Clarithromycin Extended Release for the Treatment of Mild-to-Moderate Community-Acquired Pneumonia in Adults Chest, October 1, 2005; 128(4): 2230 - 2237. [Abstract] [Full Text] [PDF]

				S. E. Pass, M. M. Gearhart, and E. J. Young Short-Course Antimicrobial Therapy for the Treatment of Pneumonia Journal of Pharmacy Practice, February 1, 2005; 18(1): 18 - 24. [Abstract] [PDF]

				J. Plouffe, D. B. Schwartz, A. Kolokathis, B. W. Sherman, P. M. Arnow, J. A. Gezon, B. Suh, A. Anzuetto, R. N. Greenberg, M. Niederman, et al. Clinical Efficacy of Intravenous followed by Oral Azithromycin Monotherapy in Hospitalized Patients with Community-Acquired Pneumonia Antimicrob. Agents Chemother., July 1, 2000; 44(7): 1796 - 1802. [Abstract] [Full Text]

				E. N. Vergis, A. Indorf, T. M. File Jr, J. Phillips, J. Bates, J. Tan, G. A. Sarosi, J. T. Grayston, J. Summersgill, and V. L. Yu Azithromycin vs Cefuroxime Plus Erythromycin for Empirical Treatment of Community-Acquired Pneumonia in Hospitalized Patients: A Prospective, Randomized, Multicenter Trial Arch Intern Med, May 8, 2000; 160(9): 1294 - 1300. [Abstract] [Full Text] [PDF]